4.0 Article

Toward Clinically Useful Neuroimaging in Depression Treatment Prognostic Utility of Subgenual Cingulate Activity for Determining Depression Outcome in Cognitive Therapy Across Studies, Scanners, and Patient Characteristics

期刊

ARCHIVES OF GENERAL PSYCHIATRY
卷 69, 期 9, 页码 913-924

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/archgenpsychiatry.2012.65

关键词

-

资金

  1. Agency for Healthcare Research and Quality
  2. Eli Lilly and Company
  3. GlaxoSmithKline
  4. National Institute of Mental Health
  5. Otsuka Inc
  6. Pfizer Inc
  7. Pharmaneuroboost
  8. Roche, Inc.
  9. Aspect Medical Systems
  10. Indevus
  11. AstraZeneca
  12. Bristol-Myers Squibb
  13. Pfizer
  14. anofi-aventis
  15. Wyeth-Ayerst
  16. Cyberonics
  17. Novartis
  18. NorthStar/St Jude Medical
  19. Medtronics
  20. Respironics
  21. National Institutes of Health [MH074807, MH082998, MH58356, MH58397, MH69618]
  22. Pittsburgh Foundation
  23. Emmerling Fund

向作者/读者索取更多资源

Context: Among depressed individuals not receiving medication in controlled trials, 40% to 60% respond to cognitive therapy (CT). Multiple previous studies suggest that activity in the subgenual anterior cingulate cortex (sgACC; Brodmann area 25) predicts outcome in CT for depression, but these results have not been prospectively replicated. Objective: To examine whether sgACC activity is a reliable and robust prognostic outcome marker of CT for depression and whether sgACC activity changes in treatment. Design: Two inception cohorts underwent assessment with functional magnetic resonance imaging using different scanners on a task sensitive to sustained emotional information processing before and after 16 to 20 sessions of CT, along with a sample of control participants who underwent testing at comparable intervals. Setting: A hospital outpatient clinic. Patients: Forty-nine unmedicated depressed adults and 35 healthy controls. Main Outcome Measures: Pretreatment sgACC activity in an a priori region in response to negative words was correlated with residual severity and used to classify response and remission. Results: As expected, in both samples, participants with the lowest pretreatment sustained sgACC reactivity in response to negative words displayed the most improvement after CT (R-2 = 0.29, > 75% correct classification of response, > 70% correct classification of remission). Other a priori regions explained additional variance. Response/remission in cohort 2 was predicted based on thresholds from cohort 1. Subgenual anterior cingulate activity remained low for patients in remission after treatment. Conclusions: Neuroimaging provides a quick, valid, and clinically applicable way of assessing neural systems associated with treatment response/remission. Subgenual anterior cingulate activity, in particular, may reflect processes that interfere with treatment (eg, emotion generation) in addition to its putative regulatory role; alternately, its absence may facilitate treatment response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据